ESTRO 2024 - Abstract Book

S1352

Clinical - Head & neck

ESTRO 2024

(TTP) as the time from the last day of SBRT to disease progression or death from any cause. Predictive factors of better clinical outcome and survival analysis were analyzed by means of Cox regression and Kaplan Meier methods, respectively.

Results:

A cohort of 48 patients, with a total of 50 metastases, was retrospectively evaluated. The median age at time of treatment was 68 years (range 37-86) and 43 patients had an ECOG PS 0-1. Oropharynx cancer (OPC) was the primary tumor subsite in 19 patients and HPV positive status was reported in 12 patients (25%). “De novo” oligometastatic pattern (79%) was observed for the majority of patients. After a median follow up of 23,5 months (range 6-109), median TTP and overall survival (OS) were 18 months (95% CI 10.5 – 25.5) and 95 months (95%CI 59 - 131), respectively (Figure 1a-b). At univariate analysis, patients aged > 70 years reported a better TTP (p 0.03; Figure 1c). No statistically significant correlation was observed in respect with gender (p 0.24), ECOG PS (p 0.24) or oligometastatic pattern (p 0.42). A positive trend for better TTP in respect with OPC versus the other primary tumor subsite was found (p 0.09). Out of 26 histologically proven metastases, 7 patients were diagnosed with OPC and 2 of them reported concordance between p16/HPV positive status of primary tumor and lung metastases. Overall, 6 patients reported grade (G) 1-2 acute toxicity and no acute G3 adverse events were observed.

Conclusion:

SBRT may improve clinical outcome prolonging time to progression and to systemic treatments in a properly selected cohort of HNSCC patients with lung-only oligometastatic disease. Distant metastases from HPV-related primary HNSCC should be tested for p16/HPV status given the clinical implications of HPV positivity for diagnosis and treatment.

Keywords: HNSCC, Lung metastases, SBRT

1898

Digital Poster